Eckert & Ziegler stock holds in the mid-€13 range as investors weigh recent research coverage
Published on 08/22/2026 at 10:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Eckert & Ziegler SE (ISIN DE0005659700) stock is trading in the mid-€13 range on Xetra, with a closing price of €13.41 on August 19, 2026, setting the stage for a modest discount versus a recent research price target of €21.00 per share.
Market data shows moderate discount to target
Per a detailed Xetra quote overview dated August 19, 2026, Eckert & Ziegler shares closed at €13.41, up 0.60% on the session with reported trading volume of 101,084 shares. The same quote page also lists a last closing price level of €13.33 and an average price target of €21.60 across covered analysts, implying that the €13.41 spot level trades roughly 37.96% below this aggregated target range.
A separate real-time price snapshot as of August 22, 2026 indicates Eckert & Ziegler at €13.47, a decline of 0.66% on the day with an intraday range between €13.39 and €13.56. This market-data overview shows the latest session performance, underscoring that the stock remains tightly anchored around the mid-€13 mark despite short-term fluctuations.
According to a news item from the Berlin-Buch campus dated August 21, 2026, a new research coverage has been initiated on Eckert & Ziegler SE with a buy recommendation and a specific price target of €21.00 per share. The Berlin-Buch news page highlights that this coverage focuses on Eckert & Ziegler as a leading supplier of isotope-based components and measurement technology, and the €21.00 price target sits 56.65% above the latest €13.41 Xetra closing level, a gap that draws attention from valuation-focused investors.
Fundamentals and recent operating context
The same Xetra-focused market overview aggregates the latest analyst expectations, indicating an average price target of €21.60 for Eckert & Ziegler shares. While the page does not spell out full quarterly revenue and earnings details, it confirms that this price objective is informed by the most recent reporting and guidance, which investors interpret as a supportive backdrop for the isotope-based medical technology business.
On the fundamentals side, Eckert & Ziegler continues to be described as a leading provider of isotope-based components for nuclear medicine and measurement technology, serving hospitals and research institutions worldwide. The Berlin-Buch research coverage summary emphasizes that the company’s core business benefits from ongoing demand in radiopharmaceuticals and diagnostic imaging, which provides recurring revenue streams and underpins the positive rating and double-digit price target premium versus current trading levels.
For investors, the spread between the mid-€13 actual share price and the €21.00 to €21.60 target range stands out as a quantified valuation signal. With the current market price sitting more than one-third below the consensus and individual price targets, the stock’s discount reflects a mix of sector risk, interest-rate-sensitive valuation, and expectations regarding upcoming financial reports. The new coverage and buy recommendation suggest that, based on the latest interim results and guidance, analysts expect earnings and cash flow to support gradual convergence toward the indicated target band.
Isotope products anchor the business model
Eckert & Ziegler’s business model is centered on isotope-based components and systems used in nuclear medicine and industrial measurement applications. These products include sealed radioactive sources for cancer therapy, calibration standards for imaging devices, and specialized isotopes used in diagnostic procedures. The company’s positioning in this niche market gives it a defensible technology footprint and long-term customer relationships with clinics, pharmaceutical developers, and research centers that rely on stable supply and regulatory-compliant handling of radioactive materials.
Demand for such products typically links to broader trends in oncology and diagnostic imaging, where growing case volumes and continuous innovation in radiopharmaceuticals drive the need for reliable isotope sources. For Eckert & Ziegler, this translates into a mix of one-off equipment deliveries and recurring revenue from consumable isotopes, providing a business base that analysts factor into their valuation work and price targets.
Stock trading context and investor view
As of the most recent Xetra session recorded on August 19, 2026, Eckert & Ziegler shares closed at €13.41, while a follow-up snapshot on August 22, 2026 shows intraday trading around €13.47. The combination of modest day-to-day price swings, meaningful volume above 100,000 shares, and a consensus target cluster around €21.00 to €21.60 gives investors a clear numerical frame for assessing potential upside and risk.
For retail investors, the key takeaway is that Eckert & Ziegler stock currently trades at a substantial discount to the levels indicated by recent research coverage and aggregated analyst targets, while its niche isotope-based product portfolio continues to underpin long-term demand in nuclear medicine and measurement technology.
Fact box
Company: Eckert & Ziegler SE
ISIN: DE0005659700
Ticker: EUZ
Exchange: Xetra
Price (as of August 19, 2026, 5:35 p.m. ET): €13.41 EUR
Market cap: Data based on current Xetra pricing
Sector / Industry: Health care - medical technology and supplies
Index membership: Listed on Xetra, not part of major US indexes
